Ligand Pharmaceuticals stock hits 52-week high at $157.54

Published 21/08/2025, 18:40
Ligand Pharmaceuticals stock hits 52-week high at $157.54

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), with a market capitalization of $3.1 billion, has reached a significant milestone with its stock hitting a 52-week high of $157.54. According to InvestingPro analysis, the stock is currently trading above its Fair Value, with analysts setting price targets between $155 and $185. This achievement underscores a robust performance over the past year, during which the company’s stock has appreciated by an impressive 51.81%. The surge in Ligand’s stock price reflects positive investor sentiment and confidence in the company’s growth prospects, supported by six analysts revising earnings estimates upward and an expected 27% revenue growth for FY2025. The 52-week high marks a period of strong market performance, bolstered by strategic initiatives and developments within the company. As Ligand continues to advance its pharmaceutical endeavors, investors remain optimistic about its future trajectory, with InvestingPro data showing a "GOOD" overall financial health score and 10+ additional exclusive insights available for subscribers.

In other recent news, Ligand Pharmaceuticals completed a $460 million convertible notes offering, which included the full exercise of the initial purchasers’ option to buy an additional $60 million in notes. The company raised approximately $445.1 million after fees and expenses from this offering. This follows the company’s earlier announcement of its intention to offer $400 million in convertible senior notes, with plans to grant purchasers an option for an additional $60 million. On the earnings front, Ligand reported second-quarter 2025 revenue of $47.6 million, marking a 15% increase year-over-year and surpassing consensus estimates by about 9%. This revenue growth was driven by strong performance in the Royalty and Captisol segments. Analysts have responded positively to Ligand’s financial results, with RBC Capital raising its price target to $185, maintaining an Outperform rating. Similarly, Oppenheimer increased its price target to $167, also maintaining an Outperform rating, citing strong royalty growth. These developments highlight the company’s recent financial and strategic activities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.